Search
 

Proposal to cut Medicare drug reimbursements could hamper care

340B Health and its members submitted comments strongly opposing the almost 30 percent proposed payment reduction, contending it would be counterproductive and would actually reduce access to care.

By Katie Kuehner-Hebert | Updated on September 13, 2017
An advocacy group says the Centers for Medicare & Medicaid Services proposed cuts to Medicare drug payments would backfire and cause those hospitals to serve less patients and provide fewer services. (Photo: Shutterstock)

In an attempt to bring down out-of-pocket drug costs for Medicare patients, the Centers for Medicare & Medicaid Services has proposed cutting Medicare drug payments to hospitals serving low-income and other disadvantaged communities in the government’s so-called 340B program. But an advocacy group for hospitals and other providers that participate in the program contend that CMS’s proposal would actually backfire and cause those hospitals to serve less patients and provide fewer services.

The 340B program, established by Congress in 1992, requires drug manufacturers to sell certain outpatient drugs at discounts to health care providers that serve low-income and other disadvantaged populations. The providers, in turn, use their 340B drug savings to serve more patients and provide more services at no cost to the government, according to 340B Health, which represents more than 1,300 hospitals and other providers participating in the program.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

Katie Kuehner-Hebert

Katie Kuehner-Hebert

Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.

More from this author

Recommended Stories

FDA approves world’s most expensive drug at $3.5M a dose

FDA approves world’s most expensive drug at $3.5M a dose

Michelle Fay Cortez |

Hemgenix is a one-off IV therapy that can cut the number of regular trips to the hospital in half for hemophilia patients – and ultimately reduce health care costs because of fewer bleeding incidents.

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2022 ALM Global, LLC. All Rights Reserved.